Resumo:
Resumo: Estudo de Ociperlimabe com Tislelizumabe em comparação com Pembrolizumabe, selecionado por PD-L1.
População: Sem terapia sistêmica prévia para NSCLC metastático; PD-L1 > 50%; ECOG < 1; avaliação central dos níveis de PD-L1 e EGFR. Critérios de exclusão: mutações conhecidas em gene EGFR, oncogene de fusão ALK, BRAF V600E, ROS1; metástase cerebral.
Contato:
Brasília/DF e Pernambuco/PE
Instituição: IDOR Distrito Federal e IDOR Pernambuco
Informações: 11 94257-9076 (WhatsApp) / 11 2109-8804
E-mail: nucleodecaptacao@idor.org
Cookie | Duração | Descrição |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |